非奈利酮的新纪元：心力衰竭患者福音？
在临床前的多项研究中，非奈利酮的抗炎和抗纤维化优势一再被证实，其潜在的疗效正在获得进一步重视。作为非甾体MRA的先锋，非奈利酮无疑为针对复杂心肾代谢疾病的治疗开辟了新的方向，更有可能最终改变我们对心力衰竭及其合并症的整体管理策略。随着未来更多临床试验的逐步推进，非奈利酮或许能够为广泛的心力衰竭患者群体带来更为切实的益处，成为心力衰竭治疗的新选择。 返回搜狐，查看更多 ...
腾讯网10 天
心肾疾病患者长期使用环硅酸锆钠治疗，能否降低高钾血症相关住院 ...
尽管既往研究表明，与短期SZC治疗的患者相比，长期接受SZC治疗的患者高钾血症相关住院率较低，但这尚未在患有心肾疾病的患者中进行评估，包括CKD、终末期肾病（ESKD）或心力衰竭（HF）。GALVANIZE ...
非奈利酮：改变心力衰竭治疗游戏规则的新希望？
非奈利酮是一种新型的非甾体盐皮质激素受体拮抗剂，于2021年获得美国食品和药物管理局（FDA）批准，用于降低与T2D相关的CKD患者的肾脏和心血管事件风险。与传统MRAs相比，非奈利酮具有更高的选择性和更短的半衰期，能够在减少副作用的同时提供更好的疗效。 FIDELIO-DKD和FIGARO-DKD试验 ...
The American Journal of Managed Care2 天
Three New Studies Explore Treatment Strategies for Heart Failure and Comorbid Conditions
Findings from the SUMMIT, Altshock-2, and FAIR-HF2 trials were presented at the American College of Cardiology 2025 Annual ...
Tirzepatide benefits people with obesity, kidney disease and heart failure
The drug tirzepatide improved kidney function and cardiovascular outcomes among patients with obesity and heart failure with ...
Medindia4 天
Tirzepatide: Combating Obesity, Kidney Disease, and Heart Failure Together
Tirzepatide offers a promising treatment for patients with obesity, chronic kidney disease, and heart failure, improving both ...
The American Journal of Managed Care6 天
New FINEARTS-HF Findings Provide Clarity on Balancing Risk and Benefit in HF, CKD
At the American College of Cardiology 2025 Annual Scientific Session, John W. Ostrominski, MD, of Brigham and Women’s Hospital, dives into the nuanced safety profile of finerenone for high-risk ...
ACC 25: tirzepatide influences clinical trajectory of patients with HFpEF and obesity
GlobalData predicts that tirzepatide is likely to be increasingly prescribed for broader cardiometabolic disease.
Managed Healthcare Executive6 天
Treatment Options for Heart Failure Expands With Finerenone | ACC 2025
Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...